Cambium Bio (ASX:CMB) EV-to-EBIT : 66.15 (As of Jun. 20, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cambium Bio's Enterprise Value is A$3.11 Mil. Cambium Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.05 Mil. Therefore, Cambium Bio's EV-to-EBIT for today is 66.15.

The historical rank and industry rank for Cambium Bio's EV-to-EBIT or its related term are showing as below:

ASX:CMB' s EV-to-EBIT Range Over the Past 10 Years
Min: -59.43 Med: -3.08 Max: 66.15
Current: 66.15

During the past 10 years, the highest EV-to-EBIT of Cambium Bio was 66.15. The lowest was -59.43. And the median was -3.08.

ASX:CMB's EV-to-EBIT is ranked worse than
89.95% of 438 companies
in the Biotechnology industry
Industry Median: 8.67 vs ASX:CMB: 66.15

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Cambium Bio's Enterprise Value for the quarter that ended in Dec. 2023 was A$0.89 Mil. Cambium Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.05 Mil. Cambium Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 5.27%.

Cambium Bio EV-to-EBIT Historical Data

The historical data trend for Cambium Bio's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio EV-to-EBIT Chart

Cambium Bio Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EV-to-EBIT

Get a 7-Day Free Trial

-3.79

-23.83

8.82

-4.61

-1.64

Cambium Bio Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-	-4.61	-	-1.64	-

Competitive Comparison of Cambium Bio's EV-to-EBIT

For the Biotechnology subindustry, Cambium Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cambium Bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cambium Bio's EV-to-EBIT falls into.

Cambium Bio EV-to-EBIT Calculation

Cambium Bio's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	3.109	/	0.047
	=	66.15

Cambium Bio's current Enterprise Value is A$3.11 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cambium Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.05 Mil.

Cambium Bio (ASX:CMB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Cambium Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	0.047	/	0.892311
	=	5.27 %

Cambium Bio's Enterprise Value for the quarter that ended in Dec. 2023 was A$0.89 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cambium Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.05 Mil.

Cambium Bio EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Cambium Bio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Cambium Bio (ASX:CMB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021

Website

https://www.regeneus.com.au

Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. It mainly develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing. The company has one operating segment being the development of innovative cell-based therapies to address significant unmet medical needs in human and veterinary health.

Cambium Bio (ASX:CMB) Headlines

No Headlines